Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC)

被引：0

作者：

Soria, J. C. ^{[1
]}

Bennouna, J. ^{[2
]}

Leighl, N. ^{[3
]}

Khuri, F. ^{[4
]}

Traynor, A. M. ^{[5
]}

Johnson, B. ^{[6
]}

Kay, A. ^{[7
]}

Blais, N. ^{[8
]}

Jehl, V. ^{[9
]}

Papadimitrakopoulou, V. ^{[10
]}

机构：

[1] Inst Gustave Roussy, Villejuif, France

[2] Ctr Rene Gauducheau, St Herblain, France

[3] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

[4] Emory Univ, Atlanta, GA 30322 USA

[5] Univ Wisconsin, Carbone Comprehens Canc Ctr, Madison, WI 53706 USA

[6] Lowe Ctr Thorac Oncol, Dana Farber Canc Inst, Boston, MA USA

[7] Novartis Pharmaceut, Florham Pk, NJ USA

[8] CHUM, Montreal, PQ, Canada

[9] Novartis Pharma AG, Basel, Switzerland

[10] Univ Texas Houston, Houston, TX USA

来源：

EJC SUPPLEMENTS | 2009年 / 7卷 / 02期

关键词：

D O I：

10.1016/S1359-6349(09)71887-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：558 / 559

页数：2